Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 1793-1798

  Aoki, Akiko ^a   Ishiguro, Shin ^a   Watanabe, Takashi ^a   Ueda, Mikito ^a   Hayashi, Yuki ^a   Akiyama, Kazufumi ^a   Kato, Kazuko ^b   Inoue, Yoshimasa ^a   Tsuchimine, Shoko ^c   Yasui Furukori, Norio ^c   Shimoda, Kazutaka ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b Sakura la Mental Clinic   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

Author keywords

Discontinuation; Major depressive disorder; Panic disorder; Paroxetine

Indexed keywords

PAROXETINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENE STRUCTURE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; OUTCOME ASSESSMENT; PANIC; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; SEROTONIN TRANSPORTER GENE LINKED POLYMORPHIC REGION; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

EID: 84907215160     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S68670     Document Type: Article

References (21)

1. Toni C, Perugi G, Frare F, Mata B, Akiskal HS. Spontaneous treatment discontinuation in panic disorder patients treated with antidepressants. Acta Psychiatr Scand. 2004;110(2):130–137.
2. Johnson DA. Depression: treatment compliance in general practice. Acta Psychiatr Scand Suppl. 1981;290:447–453.
3. Perlis RH, Mischoulon D, Smoller JW, et al. Serotonin transporter polymorphisms and adverse effects with fuoxetine treatment. Biol Psychiatry. 2003;54(9):879–883.
4. Popp J, Leucht S, Heres S, Steimer W. Serotonin transporter polymorphisms and side effects in antidepressant therapy – a pilot study. Pharmacogenomics. 2006;7(2):159–166.
5. Murphy GM, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine effcacy and adverse events in geriatric major depression. Arch Gen Psychiatry. 2004;61(11):1163–1169.
6. Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem. 1996;66(6):2621–2624.
7. Stahl SM. Essential Psychopharmacology: Neuroscientifc Basis and Practical Applications. 2nd ed. New York: Cambridge University Press; 2000.
8. Louie AK, Lewis TB, Lannon RA. Use of low-dose fuoxetine in major depression and panic disorder. J Clin Psychiatry. 1993;54(11):435–438.
9. Ishiguro S, Watanabe T, Ueda M, et al. Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder. Eur J Clin Pharmacol. 2011;67(12):1213–1221.
10. Bandelow B. Assessing the effcacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Int Clin Psy-chopharmacol. 1995;10(2):73–81.
11. Yasui-Furukori N, Nakagami T, Kaneda A, et al. Inverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disorders. Hum Psychopharmacol. 2011;26(8):602–608.
12. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389.
13. Hikida K, Inoue Y, Nouchi E, Ohkura Y. Determination of etizolam in human serum or plasma using automated column-switching high-performance liquid chromatography. Japanese Journal of Clinical Chemistry. 1990;19(4):354–359.
14. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274(5292):1527–1531.
15. Gartlehner G, Hansen RA, Carey TS, Lohr KN, Gaynes BN, Randolph LC. Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis. Int Clin Psychopharmacol. 2005;20(2):59–69.
16. Goethe JW, Woolley SB, Cardoni AA, Woznicki BA, Piez DA. Selective serotonin reuptake inhibitor discontinuation: side effects and other factors that infuence medication adherence. J Clin Psychopharmacol. 2007;27(5):451–458.
17. Freire RC, Lopes FL, Veras AB, et al. Personality traits spectrum in panic disorder and major depression. Rev Bras Psiquiatr. 2007;29(1):31–34.
18. Sen S, Burmeister M, Ghosh D. Meta-analysis of the association between a serotonin transporter promoter polymorphism (5-HTTLPR) and anxiety-related personality traits. Am J Med Genet B Neuropsychiatr Genet. 2004;127B(1):85–89.
19. Yamakawa M, Fukushima A, Sakuma K, Yanagisawa Y, Kagawa Y. Serotonin transporter polymorphisms affect human blood glucose control. Biochem Biophys Res Commun. 2005;334(4):1165–1171.
20. Sawamura K, Suzuki Y, Someya T. Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine. Eur J Clin Pharmacol. 2004;60(8):553–557.
21. Ueda M, Hirokane G, Morita S, et al. The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(3): 486–491.